
|Videos|July 30, 2018
Treatments for Relapsed and Refractory Multiple Myeloma
Treatments for Relapsed and Refractory Multiple Myeloma
Advertisement
CASE: A 72-year-old Caucasian Man With Relapsed Multiple Myeloma
September 2016
- Patient history: At the age of 72, a Caucasian man was diagnosed with multiple myeloma; R-ISS stage I
- Other relevant history includes hypertension and difficulty walking up stairs
- He was treated with lenalidomide/dexamethasone and achieved a VGPR
- Treatment duration was 9 months; patient subsequently discontinued therapy 12 months ago
June 2018
- On routine follow-up, patient complains of increasing problems with fatigue, and has rising levels of M protein
- Laboratory results:
- Hb, 9.6 g/dL
- Ca2+9.2 mg/dL
- Creatinine, 0.8 mg/dL
- M-protein, 3.0 g/dL
- 30% plasma cells in bone marrow
- Cytogenetics/FISH: del(17p)
- ECOG PS: 2
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5



































